entertainment -WSS

entertainment

author：fashion 2025-10-03 00:37:44 - browse：864

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Bill would stop addiction treatment from triggering child abuse inquiry

focus

WSS

Should insurance cover cosmetic surgery?

Louisiana bill approved classifying abortion pills as controlled substances

Analysis of telehealth claims data suggest service duplication

Protect nursing home residents from future pandemics

Why we need mandatory labeling of GMO products

J&J reports mixed data on next

focus

entertainment

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Physician executives need more than on

Medicare proposal to cover medical devices draws a mixed reaction

Chan Zuckerberg Biohub Chicago to focus on inflammation

Activists slam private health insurers over coverage restrictions

New research sheds light on how often breast cancer is overdiagnosed

Cancer drug shortages should be causing more outrage

U.S. death rates show how politics are affecting public health

United colonoscopy coverage change 'may cost lives,' doctors say

The future of health care in the House

entertainment

New research sheds light on how often breast cancer is overdiagnosed

Stroke deaths set to near 10 million globally by 2050

When women are denied an abortion, their children fare worse than peers

Chemotherapy drug shortage eases slightly but still widespread

Why Charlie Gard's case is so disturbing to Americans

New research sheds light on how often breast cancer is overdiagnosed

focus

hotspot

focus

focus